447 related articles for article (PubMed ID: 3883580)
1. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
2. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
[TBL] [Abstract][Full Text] [Related]
3. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord].
Morimoto K; Ikata T; Tounai T
Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197
[TBL] [Abstract][Full Text] [Related]
4. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of vessel wall prostacyclin by selective thromboxane synthetase inhibitor OKY 1581.
Mehta J; Mehta P; Ostrowski N
Prostaglandins Leukot Med; 1983 Sep; 12(1):49-52. PubMed ID: 6356153
[TBL] [Abstract][Full Text] [Related]
6. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise.
Shikano M; Ito T; Ogawa K; Satake T
Jpn Heart J; 1987 Sep; 28(5):663-74. PubMed ID: 3323562
[TBL] [Abstract][Full Text] [Related]
7. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats.
Gomi T; Ikeda T; Ishimitsu T; Uehara Y
Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692
[TBL] [Abstract][Full Text] [Related]
8. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M
Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome.
Niwa T; Maeda K; Shibata M; Yamada K
Clin Nephrol; 1988 Nov; 30(5):276-81. PubMed ID: 3214971
[TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
[TBL] [Abstract][Full Text] [Related]
11. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
12. Increased production of eicosanoids, TXA2, PGI2 and LTC4 in experimental spinal cord injuries.
Mitsuhashi T; Ikata T; Morimoto K; Tonai T; Katoh S
Paraplegia; 1994 Aug; 32(8):524-30. PubMed ID: 7970857
[TBL] [Abstract][Full Text] [Related]
13. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
Davenport NJ; Goldstein RE; Feuerstein GZ
J Cardiovasc Pharmacol; 1991 Apr; 17(4):641-6. PubMed ID: 1711633
[TBL] [Abstract][Full Text] [Related]
14. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528
[TBL] [Abstract][Full Text] [Related]
15. Comparison of umbilical vein models for measurement of relative prostacyclin and thromboxane production.
Mehta P; Mehta J; Crews F; Roy L; Ostrowski N; Horalek C
Prostaglandins; 1982 Dec; 24(6):743-9. PubMed ID: 6820165
[TBL] [Abstract][Full Text] [Related]
16. Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581.
Uotila P; Matintalo M; Dahl ML
Prostaglandins Leukot Med; 1983 Nov; 12(3):299-303. PubMed ID: 6419237
[TBL] [Abstract][Full Text] [Related]
17. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart.
Sakai K; Ito K; Ogawa K
J Cardiovasc Pharmacol; 1982; 4(1):129-35. PubMed ID: 6176788
[TBL] [Abstract][Full Text] [Related]
18. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on endotoxin-induced lung injury in unanesthetized sheep.
Kubo K; Kobayashi T
Am Rev Respir Dis; 1985 Sep; 132(3):494-9. PubMed ID: 3898941
[TBL] [Abstract][Full Text] [Related]
19. A new approach to antithrombotic therapy--evaluation of combined therapy of thromboxane synthetase inhibitor and very low dose of aspirin.
Nagatsuka K; Uyama O; Nakabayashi S; Yoneda S; Kimura K; Kamada T
Stroke; 1985; 16(5):806-9. PubMed ID: 3931302
[TBL] [Abstract][Full Text] [Related]
20. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites.
Gentilini P; Laffi G; Meacci E; La Villa G; Cominelli F; Pinzani M; Buzzelli G
Gastroenterology; 1988 Jun; 94(6):1470-7. PubMed ID: 3360268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
